Inactive Instrument

Flexion Therapeutics, Inc.

Equities

FLXN

US33938J1060

Biotechnology & Medical Research

Flexion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 12, 2021 at 04:06 pm EDT

Flexion Therapeutics, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 23.141 million compared to USD 32.582 million a year ago. Net loss was USD 28.556 million compared to USD 36.802 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 0.95 a year ago.

Latest news about Flexion Therapeutics, Inc.

Renovacor Names New CFO	22-03-28	MT
Pacira BioSciences Logs Higher Exparel, Iovera Sales in November	21-12-07	MT
North American Morning Briefing : Stock Futures -3-	21-11-22	DJ
Northland Securities Downgrades Flexion Therapeutics to Market Perform From Outperform, Price Target $10	21-11-19	MT
Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from NASDAQ Composite Index	21-11-19	CI
Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from S&P Global BMI Index	21-11-19	CI
Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from S&P TMI Index	21-11-19	CI
Pacira BioSciences, Inc. completed the acquisition of Flexion Therapeutics, Inc..	21-11-18	CI
Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from NASDAQ Biotechnology Index	21-11-18	CI
Flexion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
North American Morning Briefing : Stock Futures -3-	21-10-20	DJ
FLEXION THERAPEUTICS : HC Wainwright Downgrades Flexion Therapeutics to Neutral From Buy, Price Target at $10	21-10-19	MT
North American Morning Briefing : Stock Futures -3-	21-10-13	DJ
FLEXION THERAPEUTICS : BMO Capital Downgrades Flexion Therapeutics to Market Perform Rating From Outperform, Adjusts Price Target to $12 From $20	21-10-12	MT
FLEXION THERAPEUTICS : Credit Suisse Downgrades Flexion Therapeutics to Neutral from Outperform Following News of Sale to Pacira BioSciences, Lowers PT to $10 from $14	21-10-12	MT
FLEXION THERAPEUTICS : Credit Suisse Downgrades Flexion Therapeutics to Neutral From Outperform, Cuts Price Target to $10 From $14	21-10-12	MT
FLEXION THERAPEUTICS : Raymond James Downgrades Flexion Therapeutics to Market Perform From Strong Buy	21-10-12	MT
Flexion Therapeutics : Health Care Stocks Sliding in Late Monday Trading	21-10-11	MT
Sector Update: Health Care	21-10-11	MT
NASDAQ 100 : Top Midday Gainers	21-10-11	MT
Protagonist Therapeutics : Health Care Stocks Trade Lower Premarket Monday	21-10-11	MT
DJ Industrial : Wall Street Declines on Soaring Energy Prices	21-10-11	MT
Flexion Therapeutics : Agrees to Be Acquired by Pacira BioSciences; Shares Soar Pre-Bell	21-10-11	MT
DJ Industrial : Top Premarket Gainers	21-10-11	MT
Pacira BioSciences : adds non-opioid pain drugs with $427.5 million Flexion buy	21-10-11	RE

Chart Flexion Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Flexion Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the common form of arthritis. Its product candidate, ZILRETTA, is the intra-articular (IA) injection indicated for the management of OA knee pain. It is approved by Food and Drug Administration (FDA) to manage osteoarthritis knee pain. The ZILRETTA is a non-opioid therapy that employs its microsphere technology to provide pain relief. It markets ZILRETTA to prescribing physicians through its own field sales force of Musculoskeletal Business Managers (MBMs). The Company's other product candidates include FX201 and FX301. The FX201 is an IA gene therapy product candidate in clinical development for the treatment of OA. The FX301 is developed as a locally administered peripheral analgesic nerve block for management of post-operative pain.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.64%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-9.07%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs